Research programme: 1,3-beta-glucan synthase inhibitors - Daiichi SankyoAlternative Names: Arborcandin C
Latest Information Update: 13 May 2008
At a glance
- Originator Daiichi Sankyo Company
- Class Cyclic peptides
- Mechanism of Action Cell wall inhibitors; Glucan synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 12 May 2003 Preclinical trials in Mycoses in Japan (unspecified route)